Latest Breaking News On - Adhera therapeutics - Page 1 : comparemela.com

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoRussian federationStephen parkerDennis riedlMonte carloSimon turtonActa neuropatholBiosciences incCompany issued ordinaryColumbia universityUniversity of albertaAdss of the companyUniversity of texasArmistice capital master fund ltd

Biodexa Pharmaceuticals - Foray into T1D expands business scope

Biodexa Pharmaceuticals - Foray into T1D expands business scope
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterAdhera therapeuticsDie performance strategieAssets sie

Adhera Therapeutics, Inc (OTCMKTS:ATRX) Sees Significant Growth in Short Interest

Adhera Therapeutics, Inc. (OTCMKTS:ATRX – Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 14,600 shares, a growth of 7,200.0% from the December 31st total of 200 shares. Based on an average trading volume of 317,100 shares, […]

Adhera therapeutics incAdhera therapeutics company profileMarina biotech incAdhera therapeuticsGet free reportMarina biotechAdhera therapeutics dailyOtcmkts atrx

Biodexa Announces Closing Of $6 0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Announces Closing Of $6 0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomEdison groupBukwang pharmaceuticals co ltdProspectus departmentBiodexa pharmaceuticalsPfizer incExchange agreementMelior pharmaceuticalsi incLadenburg thalmann coExchange commissionAdhera therapeutics incUnderwritten public offeringIncluding full exercise of overallotmentTypei diabetes

Biodexa Announces Closing Of $6 0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Pharmaceuticals PLC, , a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the.

United statesNew yorkUnited kingdomMelior pharmaceuticalsi incEdison groupExchange commissionExchange agreementBiodexa pharmaceuticalsAdhera therapeutics incProspectus departmentGlobenewswire incBukwang pharmaceuticals co ltdPfizer incLadenburg thalmann coUnderwritten public offeringIncluding full exercise of overallotment